Cargando…

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP

BACKGROUND: Plasma assays for the detection of Alzheimer’s disease neuropathological changes are receiving ever increasing interest. The concentration of plasma glial fibrillary acidic protein (GFAP) has been suggested as a potential marker of astrocytes or recently, amyloid-β burden, although this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiotis, Konstantinos, Johansson, Charlotte, Rodriguez-Vieitez, Elena, Ashton, Nicholas J., Blennow, Kaj, Zetterberg, Henrik, Graff, Caroline, Nordberg, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496408/ https://www.ncbi.nlm.nih.gov/pubmed/37697307 http://dx.doi.org/10.1186/s13024-023-00647-y

Ejemplares similares

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study
por: Thordardottir, Steinunn, et al.
Publicado: (2018)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
por: Vilaplana, Eduard, et al.
Publicado: (2020)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
por: Schöll, Michael, et al.
Publicado: (2015)

Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
por: Bucci, Marco, et al.
Publicado: (2023)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

GFAP hyperpalmitoylation exacerbates astrogliosis and neurodegenerative pathology in PPT1-deficient mice
por: Yuan, Wei, et al.
Publicado: (2021)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism
por: Smailovic, Una, et al.
Publicado: (2020)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
por: Chiotis, Konstantinos, et al.
Publicado: (2015)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study
por: O'Connor, Antoinette, et al.
Publicado: (2023)

Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer’s continuum
por: Salvadó, Gemma, et al.
Publicado: (2022)

Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer’s disease
por: Levitis, Elizabeth, et al.
Publicado: (2022)

GFAp and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial
por: Humaloja, Jaana, et al.
Publicado: (2022)

Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults
por: Huebschmann, Nathan A., et al.
Publicado: (2020)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

GFAP Isoforms in Adult Mouse Brain with a Focus on Neurogenic Astrocytes and Reactive Astrogliosis in Mouse Models of Alzheimer Disease
por: Kamphuis, Willem, et al.
Publicado: (2012)

Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease
por: Pera, Marta, et al.
Publicado: (2012)

CSF proteomics in autosomal dominant Alzheimer’s disease highlights parallels with sporadic disease
por: van der Ende, Emma L, et al.
Publicado: (2023)

Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer’s disease variants: AβPParc and PSEN1DE9
por: Lemoine, Laetitia, et al.
Publicado: (2020)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Comparison of subtyping methods for neuroimaging studies in Alzheimer’s disease: a call for harmonization
por: Mohanty, Rosaleena, et al.
Publicado: (2020)

The Importance of Radiologic Imaging Modalities in Autosomal Dominant Polycystic Kidney Disease
por: Nadal Bosch, Jorge, et al.
Publicado: (2022)

Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer’s disease
por: Nicolas, Gaël, et al.
Publicado: (2018)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype
por: O'Connor, Antoinette, et al.
Publicado: (2021)

Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease
por: Huss, André, et al.
Publicado: (2022)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species
por: Oliveira, Francisco, et al.
Publicado: (2018)

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease
por: Franzmeier, Nicolai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9m7kgejkt8bmnm5ubhcbfkirus